Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine-Reference-Cited by-同舟云学术

Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine

Published:2024-05-30 Issue:8 Volume:38 Page:1267-1269
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Rubenstein Emma¹,Diemer Myriam¹,Goldwirt Lauriane²,Lascoux-Combe Caroline¹,Chaix Marie-Laure³,Rami Agathe¹,Ponscarme Diane¹,Lafaurie Matthieu¹,Denis Blandine¹,De Castro Nathalie¹,Gras Julien¹,Liegeon Geoffroy¹,Sellier Pierre-Olivier¹,Deville Laure⁴,Chevret Sylvie⁵,Delaugerre Constance³,Molina Jean-Michel¹

Affiliation:

1. Department of Infectious Diseases, Saint Louis and Lariboisiere Hospitals, Université Paris Cité

2. Department of Pharmacology

3. Department of Virology

4. Department of Pharmacy, Saint Louis Hospital

5. Department of Biostatistics, Saint Louis Hospital, Université Paris Cité Paris, France.

Abstract

In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence interval (CI) 1.7–29.5], P = 0.01] and three months (OR = 5.6 [95% CI 1.3–29.7], P = 0.03), and with high BMI at 1 month (OR = 1.3 [95% CI 1.1–1.6], P = 0.007).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference13 articles.

1. Long-acting injectable antiretrovirals for HIV treatment and prevention;Spreen;Curr Opin HIV AIDS,2013

2. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, noninferiority trial;Margolis;Lancet,2017

3. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection;Orkin;N Engl J Med,2020

4. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression;Swindells;N Engl J Med,2020

5. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study;Orkin;Lancet HIV,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic failure reported with HIV long‐acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024;HIV Medicine;2024-09-05

2. Appropriateness of virological monitoring with long-acting injectable cabotegravir and rilpivirine;Journal of Antimicrobial Chemotherapy;2024-07-27